YAVNE, Israel, March 20, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd., a fully-integrated, biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, announced today the pricing of its initial public offering of 5,000,000 ordinary shares at a price to the public of $14.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on March 20, 2014 under the symbol "MDWD." MediWound has granted the underwriters a 30-day option to purchase up to 750,000 additional shares at the initial public offering price.
Credit Suisse Securities (USA) LLC, Jefferies LLC and BMO Capital Markets Corp. are acting as joint lead book-running managers for the offering. Oppenheimer & Co. is acting as co-manager.
The offering of these securities will be made only by means of a written prospectus. A copy of the prospectus related to the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, or by phone (800) 221-1037 or Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY, 10022 or by telephone at 877-547-6340.
A registration statement relating to the initial public offering has been filed with and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.